The UK's National Institute for Health and Care Excellence is reconsidering two Alzheimer's disease treatments after initially rejecting them for being too expensive. The regulator will reassess Eli Lilly's donanemab (marketed as Kisunla) and Eisai's Leqembi following successful appeals from the pharmaceutical companies.
NICE had previously determined that both drugs did not meet cost-effectiveness thresholds for the UK's National Health Service. The initial rejections came despite the treatments representing new options for patients with early-stage Alzheimer's disease, a condition with limited therapeutic alternatives.